Serum exosomal microRNA‐766‐3p expression is associated with poor prognosis of esophageal squamous cell carcinoma

Liu, Shuang; Lin, Zheng; Zheng, Zerong; Rao, Wenqing; Lin, Yulan; Chen, Huilin; Xie, Qianwen; Chen, Yuanmei; Hu, Zhijian

doi:10.1111/cas.14550

Cited by 30 publications

(23 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Data are presented as the means ± SD. *P < 0.01. or cell lines than in normal group (Chen et al, 2017;Liu et al, 2020). Similarly, our findings via real-time quantitative PCR are consistent with those from previous studies.…”

Section: Discussionsupporting

confidence: 92%

“…miR-766-3p has recently been recognized as a tumor suppressor through the β-catenin pathway in several tumors. miR-766-3p was lower in renal cell carcinoma and hepatocellular carcinoma specimens or cell lines than in normal group ( Chen et al, 2017 ; Liu et al, 2020 ). Similarly, our findings via real-time quantitative PCR are consistent with those from previous studies.…”

Section: Discussionmentioning

confidence: 88%

“…miRNAs are also identified important in the progression of OS by regulating cell proliferation, EMT, and metastasis ( Leichter et al, 2017 ; Fellenberg et al, 2019 ; Luo et al, 2019 ; Zhang K. et al, 2020 ). miR-766-3p, a tumor suppressor microRNA, is reported to down-regulated in several types of tumor, was remarkably correlated with poor clinical outcomes ( Liu et al, 2020 ; Zhou et al, 2020 ). Nevertheless, to date, there has been no detailed investigations into the functions of miR-766-3p, and the underling mechanisms is far from being fully understood in OS.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

miR-766-3p Targeting BCL9L Suppressed Tumorigenesis, Epithelial-Mesenchymal Transition, and Metastasis Through the β-Catenin Signaling Pathway in Osteosarcoma Cells

Zhang

Chen

Liu

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Accumulating evidence has indicated that abnormal microRNAs (miRNAs) serve critical roles in carcinogenesis and development of osteosarcoma (OS). The purpose of the present study was to elucidate the relationship between miR-766-3p and development of osteosarcoma and explore the potential mechanism. In this study, we found that miR-766-3p was the most downregulated miRNA by analyzing GSE65071 from the GEO database. miR-766-3p was lowly expressed in OS tissue samples and cells, and high miR-766-3p expression repressed the malignant level of OS, including cell proliferation, EMT, migration, and invasion in vitro and in vivo. B-Cell Lymphoma 9-Like Protein (BCL9L) was negatively associated with miR-766-3p expression in OS cells and tissue samples and was validated as the downstream target by luciferase reporter assay and western blotting. Rescue experiment indicated that BCL9L could restore the influence of miR-766-3p on OS cells. In addition, the β-Catenin/TCF-4 signal pathway was demonstrated to be related to the miR-766-3p/BCL9L axis. In summary, miR-766-3p, a negative regulator of BCL9L, plays the role of tumor metastasis suppressor via the β-catenin signaling pathway in the progression of OS.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 88%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

miR-766-3p Targeting BCL9L Suppressed Tumorigenesis, Epithelial-Mesenchymal Transition, and Metastasis Through the β-Catenin Signaling Pathway in Osteosarcoma Cells

Zhang

Chen

Liu

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…MiR-191-5p is believed to act as a tumor promoter: elevated miR-191-5p levels have been correlated with the advanced stages, metastasis, and high pathological grade of hepatocellular carcinoma [ 63 ]. Serum exosomal miR-766-3p is also thought to be a prognostic marker for esophageal squamous cell carcinoma with its serum expression being associated with poor prognosis and a significantly worse survival [ 64 ]. In addition, miR-766 acts as an oncogene in the development of colorectal cancer and its overexpression promotes cell proliferation in this disease [ 65 ].…”

Section: Discussionmentioning

confidence: 99%

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients

Robak

Dróźdż

Jarych³

et al. 2020

Cancers

View full text Add to dashboard Cite

Bortezomib is the first-in-class proteasome inhibitor, commonly used in the treatment of multiple myeloma (MM). The mechanisms underlying acquired bortezomib resistance in MM are poorly understood. Several cell-free miRNAs have been found to be aberrantly regulated in MM patients. The aim of this pilot study was to identify a blood-based miRNA signature that predicts bortezomib-based therapy efficacy in MM patients. Thirty MM patients treated with bortezomib-based regimens were studied, including 19 with refractory disease and 11 who were bortezomib sensitive. Serum miRNA expression patterns were identified with miRCURY LNA miRNA miRNome PCR Panels I+II (Exiqon/Qiagen). Univariate analysis found a total of 21 miRNAs to be differentially expressed in patients with MM according to bortezomib sensitivity. Multivariate logistic regression was created and allowed us to discriminate refractory from sensitive patients with a very high AUC of 0.95 (95%CI: 0.84–1.00); sensitivity, specificity and accuracy were estimated as 0.95, 0.91, and 0.93. The model used expression of 3 miRNAs: miR-215-5p, miR-181a-5p and miR-376c-3p. This study is the first to demonstrate that serum expression of several miRNAs differs between patients who are bortezomib refractory and those who are sensitive which may prove useful in studies aimed at overcoming drug resistance in MM treatment.

show abstract

“…Various novel and highly sensitive miRs are identified in predicting the prognosis of ESCC. For instance, miR‐155 was reported to act as a diagnostic and prognostic biomarker for ESCC, 13 miR‐301a‐3p regulated the esophageal squamous cell proliferation via targeting Phosphatase and tensin homolog deleted on chromosome 10 (PTEN), 14 miR‐25‐3p was found to target PTEN to regulate esophageal cancer cell migration, invasion, and apoptosis via the phosphatidylinositol 3‐kinase/protein kinase B (PI3K/AKT) pathway, 15 and serum exosomal miR‐766‐3p expression was associated with poor prognosis of ESCC 16 . Taken together, all these findings reveal that application of specific miRs based on the dysregulation of them can assist early diagnosis and prognosis of patients with ESCC.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‐210 targets FBXO31 to inhibit tumor progression and regulates the Wnt/β‐catenin signaling pathway and EMT in esophageal squamous cell carcinoma

et al. 2021

View full text Add to dashboard Cite

Evidence from previous studies showed that the dysregulation of microRNA (miR) is frequently associated with tumor progression. The aberrant miR‐210 expression has been identified in a variety of tumors. However, its biological roles in esophageal squamous cell carcinoma (ESCC) still need further elucidation. Thus, in the current study we explore the roles of miR‐210 in ESCC progression. The findings of our study reveal that miR‐210 is down‐regulated in ESCC, which indicates poor prognosis and aggressive tumor progression. Moreover, miR‐210 restoration was found to enhance ESCC viability, invasion, and migration abilities. F‐Box only protein 31 (FBXO31) was confirmed to be one of the targets of miR‐210 in ESCC cells. Results also revealed that miR‐210 played crucial roles in regulating ESCC cell epithelial‐mesenchymal transition (EMT) and Wnt/β‐catenin signaling. In conclusion, data show that miR‐210 serves as an anti‐ESCC miR via down‐regulation of FBXO31 and regulation of EMT and Wnt signaling, suggesting that the miR‐210/FBXO31 axis may function as promising therapeutic targets and effective prognostic markers for ESCC patients.

show abstract

Serum exosomal microRNA‐766‐3p expression is associated with poor prognosis of esophageal squamous cell carcinoma

Abstract: This is an open access article under the terms of the Creat ive Commo ns Attri bution-NonCo mmerc ial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cited by 30 publications

References 32 publications

miR-766-3p Targeting BCL9L Suppressed Tumorigenesis, Epithelial-Mesenchymal Transition, and Metastasis Through the β-Catenin Signaling Pathway in Osteosarcoma Cells

miR-766-3p Targeting BCL9L Suppressed Tumorigenesis, Epithelial-Mesenchymal Transition, and Metastasis Through the β-Catenin Signaling Pathway in Osteosarcoma Cells

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients

MicroRNA‐210 targets FBXO31 to inhibit tumor progression and regulates the Wnt/β‐catenin signaling pathway and EMT in esophageal squamous cell carcinoma

Contact Info

Product

Resources

About